Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Department of Surgical and Oncological Sciences, Section of Medical Oncology, University of Palermo, Via del Vespro 127, Palermo, Italy.
Cancer Treatment Reviews (Impact Factor: 6.02). 11/2010; 36 Suppl 3:S56-61. DOI: 10.1016/S0305-7372(10)70021-9
Source: PubMed

ABSTRACT An important molecular target for metastatic CRC treatment is the epidermal growth factor receptor (EGFR). Many potential biomarkers predictive of response to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) have been retrospectively evaluated, including EGFR activation markers and EGFR ligands activation markers. With regard to the "negative predictive factors" responsible for primary or intrinsic resistance to anti-EGFR antibodies a lot of data are now available. Among these, KRAS mutations have emerged as a major predictor of resistance to panitumumab or cetuximab in the clinical setting and several studies of patients receiving first and subsequent lines of treatment have shown that those with tumors carrying KRAS mutations do not respond to EGFR-targeted monoclonal antibodies or show any survival benefit from such treatments. The role of B-RAF mutations, mutually exclusive with KRAS mutations, in predicting resistance to anti-EGFR mAbs is not yet consolidated. It therefore appears that BRAF mutations may play a strong negative prognostic role and only a slight role in resistance to anti-EGFR Abs.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal cancer (CRC) is the second leading cause of cancer-related death. Despite the progress that has been made towards the identification of the molecular mechanisms involved in CRC, currently there are many unclear points. The current opinion is that microsatellite instability (MSI), CpG island methylator phenotype (CIMP) and chromosomal instability (CIN) seem to play a significant role. MSI is related to point mutations in defect mismatch repair system of DNA. There are two well-established MSI phenotypes: MSI-high (MSI-H) and MSI-low (MSI-L or MSS). CIN refers to a different cellular event which originates from the presence of an abnormal chromosome complement or number. CIMP is the third most commonly involved event, and is defined by widespread methylation of CpG islands of suppressor promoters, with two phenotypes: CIMP-high and CIMP-low which interact with MSI or CIN status V-raf murine sarcoma viral oncogene homolog B (BRAF) is a serine-threonine protein kinase that acts as a downstream effector of the Kirsten rat sarcoma viral oncogene homolog (KRAS) pathway. Various studies have revealed that BRAF V600E mutations appear to be a valid indicator of poor prognosis. KRAS is a proto- oncogene which encodes a GTP-ase involved in cellular response to extracellular stimuli. Its prognostic value is still controversial. However, wild-type KRAS is associated with better response to Endothelial Growth Factor Receptor inhibitors combined with standard chemotherapy. Loss of Heterozygosity, especially involving 18q, is a well-known potential mechanism for tumorigenesis that has been studied in CRC. Vascular endothelial growth factor is a pro-angiogenic factor linked with the aggressiveness of CRC. Emerging data show that cycloxygenase 2 overexpression is significantly associated with worse outcomes in CRC. Recent studies highlight mi-croRNAs as promising prognostic biomarkers. More specifically, the down-regulation of miR-451, miR-625, miR-29c, miR-126, miR-129 and miR133 is purported to be a poor prognostic factor, while miR-224 was overexpressed in CRC.
    Anticancer research 05/2014; 34(5):2061-8. · 1.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinical and clinical development. The aim of this review is to provide a comprehensive overview of the state of art, focusing on the new emerging strategies in the personalized treatment of gastrointestinal tumors.
    Expert Review of Gastroenterology and Hepatology 06/2014; · 2.55 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Colorectal cancer (CRC) is one of the most common human malignant diseases and the second leading cause of cancer-related deaths worldwide. The treatment of advanced CRC has improved significantly in recent years. With the emergence of two targeted antibodies, cetuximab (Erbitux), an anti-epidermal growth factor receptor monoclonal antibody and bevacizumab (Avastin), a vascular endothelial growth factor monoclonal antibody, the treatment of metastatic CRC has entered the era of personalized therapy. Predictive and prognostic biomarkers have, and will continue to, facilitate the selection of suitable patients and the personalization of treatment for metastatic CRC (mCRC). In this review, we will focus primarily on the important progresses made in the personalized treatment of mCRC and discuss the potentially novel predictive and prognostic biomarkers for improved selection of patients for anti-cancer treatment in the future.
    World Journal of Gastroenterology 04/2014; 20(14):3858-3874. · 2.43 Impact Factor


Available from
May 26, 2014